www.hhs.gov U.S. Department of Health and Human Services
Activity Outline
FDA Grand Rounds: FDA’s Global Substance Registration System (GSRS) Unique Ingredient Identifiers (UNIIs) Uniquely Define Substances in FDA-regulated Products.
June 8, 2023
Virtual-Zoom Platform

Activity Coordinators:
Sharron Watson (Sharron.Watson@fda.hhs.gov),  Rokhsareh Shahidzadeh (rokhsareh.shahidzadeh@fda.hhs.gov)
Series Description

The FDA Grand Rounds is webcast every other month to highlight cutting-edge research underway across the agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities.

Lecture Description
Globalization has spurred an ever-increasing number of imported FDA-regulated products and ingredients. It has also driven the growing movement of clinical trials abroad. FDA's Health Informatics team has been working closely with the National Institutes of Health (NIH) and international stakeholders to advance the knowledge-sharing required to tackle globalization's impacts on our nation's public health. The FDA team has developed the Global Substance Registration System (GSRS) to help create the tools, standards, and approaches for uniquely identifying substances in FDA-regulated products.

The GSRS has unique data models based on the International Organization for Standardisation (ISO) 11238 standard, which enables FDA to accurately identify ingredient substances such as drugs, botanicals, biologics, and cosmetics. Instead of relying on names--which vary across regulatory domains, countries, and regions-the GSRS knowledgebase makes it possible for substances to be defined by standardized, scientific descriptions that are now used by our partners worldwide. All substances are assigned Unique Ingredient Identifiers (UNIIs), which were created to meet FDA's specific needs. Whereas traditional databases might exclude or ambiguously label certain ingredients, leading to misinformation and serious safety issues, these data models make it easy for researchers, clinicians, and consumers to find what ingredient substances are contained in commercial products that are domestically and foreign-sourced. The database also includes impurities, metabolites, starting materials, and synthetic intermediates for human medicinal products.

The GSRS is leading the world in establishing the framework for databasing substances, making it possible to eventually track substances from their inception to post-marketing through the supply chain and help alleviate drug shortages.

This presentation will highlight UNIIs and the various types of substances captured as well as linking substances to products, applications, clinical trials, adverse events, quality and manufacturing information within the GSRS framework.
  • FDA's Global Substance Registration System. https://www.fda.gov/industry/fda-data-standards-advisory-board/fdas-global-substance-registration-system Updated September 29, 2022.
  • Peryea T, Southall N, Miller M, Katzel D, Anderson N, Neyra J, Stemann S, Nguyễn ÐT, Amugoda D, Newatia A, Ghazzaoui R. Global Substance Registration System: consistent scientific descriptions for substances related to health. Nucleic Acids Research, Volume 49, Issue D1, 8 January 2021, Pages D1179–D1185, https://doi.org/10.1093/nar/gkaa962.
  • ISO 11238:2018 Health informatics — Identification of medicinal products — Data elements and structures for the unique identification and exchange of regulated information on substances, Edition 2, Published July 2018, https://www.iso.org/standard/69697.html.
Series Objectives
  • Discuss the research conducted at the FDA
  • Explain how FDA science impacts public health
Learning Objectives After completion of this activity, the participant will be able to:
  • Describe how GSRS accurately registers and manages records
  • Discuss how a substance search is done, and how its record interpreted.
Target Audience
This activity is intended for physicians, pharmacists, nurses, and other scientists within the agency and external scientific communities.

Lecture 1 June 8, 2023
Time Topic Speaker
12:00 - 1:00 PM EDT FDA’s Global Substance Registration System (GSRS) Unique Ingredient Identifiers (UNIIs) Uniquely Define Substances in FDA-regulated Products. Marlene Kim, PhD
Continuing Education Accreditation
Jointly Accredited Provider
In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ICPE Credit
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-23-002-L99-P for 1.00 contact hour(s).
FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).
Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.

Important Note regarding completion of evaluations and receiving credit
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.

  • Kim, Marlene, PhD, Chemist, FDA - nothing to disclose

Planning Committee
  • Dinatale, Miriam, DO, Team Leader, Food and Drug Administration - nothing to disclose
  • Pfundt, Tiffany, PharmD, Senior Advisor, HHS/ASPR - nothing to disclose
  • Wheelock, Leslie, RN, MS, Director, OSPD, FDA, OC, OCS, OSPD - nothing to disclose

CE Consultation and Accreditation Team
  • Bueide, Rachel E., MPhil, Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
  • Bryant, Traci, M.A.T., Lead Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
  • Wood, Sara, Accreditation Program Administrator, CECAT, FDA/CDER/OEP/DLOD - nothing to disclose
Any relationship shown above in italics has been divested within the last 24 months and is therefore considered mitigated.
All relevant financial relationships have been mitigated.
Registration Information
Registration is complimentary, therefore refunds are not applicable.
ACCME Joint Accreditation
  • This warning banner provides privacy and security notices consistent with applicable federal laws, directives, and other federal guidance for accessing this Government system, which includes (1) this computer network, (2) all computers connected to this network, and (3) all devices and storage media attached to this network or to a computer on this network.
  • This system is provided for Government-authorized use only.
  • Unauthorized or improper use of this system is prohibited and may result in disciplinary action and/or civil and criminal penalties.
  • Personal use of social media and networking sites on this system is limited as to not interfere with official work duties and is subject to monitoring.
  • By using this system, you understand and consent to the following:
    • The Government may monitor, record, and audit your system usage, including usage of personal devices and email systems for official duties or to conduct HHS business. Therefore, you have no reasonable expectation of privacy regarding any communication or data transiting or stored on this system. At any time, and for any lawful Government purpose, the government may monitor, intercept, and search and seize any communication or data transiting or stored on this system.
    • Any communication or data transiting or stored on this system may be disclosed or used for any lawful Government purpose.